Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.
Rivas EI, Linares J, Zwick M, Gómez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Lladó A, Bardia L, Pérez-Núñez I, Martínez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celià-Terrassa T, Burgués O, Gomis RR, Albanell J, Calon A.
Rivas EI, et al. Among authors: llado a.
Nat Commun. 2022 Sep 9;13(1):5310. doi: 10.1038/s41467-022-32782-3.
Nat Commun. 2022.
PMID: 36085201
Free PMC article.